Last updated: July 27, 2026
Vorasidenib is an oral, IDH1/IDH2 dual inhibitor (IDH1/2 mutant tumors) positioned for earlier-stage disease in low-grade glioma and oligodendroglioma. The near-term commercialization thesis depends on (1) sustained uptake post-approval in progressive low-grade glioma, (2) label expansion into broader earlier lines, and (3) competitive differentiation versus IDH-targeted rivals through dosing, safety, and survival readouts. Pricing and volume capture will hinge on payer acceptance of long-duration oral therapy, specialty pharmacy logistics, and penetration of molecular testing (IDH mutation status).
What is vorasidenib’s current clinical trial and FDA approval status?
Short answer: Vorasidenib has FDA approval for IDH-mutant, non–1p/19q-codeleted, grade 2 low-grade glioma that has progressed after surgery, based on pivotal progression-free survival benefit. Additional readouts in earlier-stage and combination settings drive the pipeline value.
Which pivotal trials define the current label?
- INDIGO (Phase 3)
- Population: IDH1/2–mutant grade 2 glioma
- Endpoint: progression-free survival (PFS) and overall survival (OS) follow-up
- Role in label: establishes disease-control benefit that underpins approval positioning
What ongoing studies could extend the market?
Key value inflection points are survival durability and earlier-line expansion.
- Earlier disease settings (neoadjuvant/adjuvant or post-surgical minimal residual disease concepts)
- Target: shift vorasidenib to earlier treatment lines where prevalence is higher and treatment duration increases.
- Combination studies
- Target: improve depth of response and potentially overcome resistance mechanisms through rational partners (radiation, chemo, or other targeted agents).
- Biomarker-stratified studies
- Target: sharpen uptake among molecular subgroups defined by IDH mutation type and tumor genotype.
Market impact framing: each positive expansion that increases eligible patient share by even low-single-digit percentages can move revenue materially because glioma therapy often runs for years.
What do vorasidenib clinical trial results show for efficacy and safety so far?
Short answer: The core efficacy signal is improved PFS versus comparator, with a safety profile consistent with oral targeted therapy (class-linked events) and manageable discontinuation rates in clinical practice.
Efficacy readouts investors watch
- PFS at fixed timepoints
- Drives payer confidence and prescriber uptake in glioma where OS can lag.
- OS maturity
- Determines long-term competitive positioning and whether second-line use expands.
- Subgroup consistency
- Critical for label breadth: IDH1 versus IDH2 mutation, grade 2 heterogeneity, and molecular codeletion patterns.
Safety and tolerability profile
- Adverse events requiring monitoring typically relate to on-target pathway modulation and general targeted-therapy toxicities.
- Dose interruptions and discontinuation rates are key for real-world adherence since vorasidenib is chronic therapy.
When does vorasidenib lose exclusivity in the US and other key markets?
Short answer: A precise exclusivity timeline requires Orange Book patent and regulatory exclusivity record granularity; the analysis here is structured around the standard exclusivity framework but cannot produce exact dates without the specific listed patents and their expiry/expiration status.
What drives exclusivity for small molecules like vorasidenib?
- US patent term expiration (filing dates, patent term adjustment, and patent-specific expiry)
- Regulatory exclusivities (new chemical entity, new therapeutic indication, pediatric exclusivity if applicable)
- Patent term adjustments and statutory extensions that can extend or reduce effective exclusivity windows
Practical implication for generic/biosimilar risk
- For a small molecule oncology drug, generics depend on patent-freedom on at least:
- composition-of-matter patents,
- method-of-use patents for each labeled indication, and
- formulation or manufacturing patents that survive composition challenges.
What patents protect vorasidenib and how strong is the patent estate?
Short answer: A typical small-molecule IDH inhibitor estate includes composition-of-matter and method-of-use claims; the strength depends on whether key claims cover:
- the specific vorasidenib compound,
- crystalline form or solid-state properties, and
- the specific glioma treatment regimen.
How to assess strength for litigation risk
- Claim breadth: whether composition claims cover salt forms, polymorphs, and solvates
- Secondary patents: whether method-of-use claims are narrow enough to be designed around
- Generic design-around feasibility: whether alternative dosing schedules or non-infringing intermediates exist
- Family size: number of continuations and jurisdictional coverage
How many patent families likely cover key revenue pools
Because vorasidenib addresses multiple clinical scenarios (grade 2 glioma progression and potential label expansion), the estate often bifurcates into:
- composition-of-matter families
- method-of-use families per tumor subtype or clinical stage
- formulation/manufacturing families for stability and bioavailability
What patent litigation or Paragraph IV challenges affect vorasidenib?
Short answer: The presence of active or threatened Paragraph IV litigation depends on FDA ANDA filings and Orange Book listings; producing a correct litigation map requires the exact Orange Book patent list and case dockets.
What to monitor
- ANDA submissions with Paragraph IV certifications to each Orange Book-listed patent
- District court filing dates that trigger the 30-month stay
- Settlement agreements that define:
- launch date carve-outs,
- non-infringement concessions,
- authorized generic timing, and
- exclusivity carve-out geography and strength
What is the Orange Book status of vorasidenib?
Short answer: Orange Book status determines the patent list that controls generic entry risk. A completed analysis requires:
- the specific FDA NDA number,
- the Orange Book listed patents,
- the listed expiration dates,
- whether any patents are tied to pediatric exclusivity or exclusivity periods.
Without the underlying Orange Book listing, a date-accurate Orange Book table cannot be generated.
How does vorasidenib compare with other IDH inhibitors in glioma by efficacy, safety, and market positioning?
Short answer: Market share depends on clinical differentiation (PFS and OS trajectory), safety tolerability, and whether the label expands to earlier lines where eligible populations are larger.
Comparison framework used by payers and health technology assessments
- Clinical endpoints: PFS magnitude, response durability, and OS maturity
- Adverse-event profile: discontinuation rates and chronic monitoring needs
- Administration: oral dosing schedule and adherence burden
- Coverage criteria: payer’s proposed line-of-therapy rules and molecular test prerequisites
Commercial implication
IDH inhibitors compete on:
- molecular testing capture rates,
- specialist prescribing comfort with long-duration oral regimens, and
- how quickly subsequent-line treatment becomes standard if first-line uptake is constrained by prior surgery or radiation timing.
What generic entry risks exist for vorasidenib?
Short answer: For a targeted oncology small molecule, the earliest credible generic threat typically comes after composition-of-matter and key method-of-use patents expire or if challengers successfully invalidate or design around at least one dominant barrier.
Generic launch scenario structure
- Scenario A: delayed entry due to multiple blocking patents
- Multiple independent Orange Book patents continue to block ANDA approval.
- Scenario B: partial entry via design-around
- Changes in form factor, salt form, or method-of-use scope reduce infringement risk.
- Scenario C: settlement early in the 30-month stay window
- Generic launches sooner than patent expiry if settlement grants a date-certain launch.
What formulations are protected by vorasidenib patents and what are the manufacturing/IP barriers?
Short answer: Formulation and solid-state patents often matter for small molecules because they protect:
- crystalline forms,
- particle size and distribution,
- stability and dissolution properties that affect bioavailability.
Why formulation patents increase barriers
- Even when the API is generic-ready, generic sponsors must meet bioequivalence while avoiding infringing:
- protected polymorphs/solvates,
- protected manufacturing routes,
- protected release profiles for specific dose strengths.
What a non-infringing pathway looks like
- A credible challenge requires demonstrating non-infringement or invalidity against the specific formulation claims, not just the composition claim.
How should market sizing and revenue projection for vorasidenib be built?
Short answer: Build projection from (1) diagnosis and molecular test rates, (2) eligible patient funnel by stage and line, (3) treatment persistence, (4) pricing and reimbursement net-to-wholesale, and (5) competitive displacement over time.
Core revenue model components
- Eligible patients per year
- Glioma incidence and prevalence are the foundation.
- Apply IDH mutation frequency and molecular testing adoption.
- Share of eligible treated with vorasidenib
- Driven by label scope, clinical guideline adoption, and payer criteria.
- Duration of therapy and persistence
- Oral targeted oncology therapy often persists until progression or intolerance.
- Net price
- Influenced by specialty drug contracting, rebates, and payer negotiation.
- Discontinuation and dose intensity
- Impacts pill volume and cost per treated patient.
Three-stage projection approach
- Stage 1: launch ramp
- Specialty center adoption, early payer contracting, initial guideline uptake.
- Stage 2: label expansion and broader line penetration
- Captures larger patient cohorts if trial readouts support expanded indications.
- Stage 3: competitive pressure and erosion
- Generic threats and rival targeted oncology agents reduce share.
Vorasidenib market projection: base, upside, and downside scenarios
Short answer: A high-credible range requires a numeric input set (pricing, patient numbers, persistence curves). The absence of those exact inputs prevents a correct quantified forecast.
Scenario logic (directional, decision-ready)
- Downside drivers
- slower-than-expected adoption due to molecular testing constraints
- payer restriction to narrow subgroups or later line only
- higher discontinuation from tolerability than clinical trials suggest
- negative or delayed OS data reducing guideline enthusiasm
- Upside drivers
- earlier-line label expansion
- higher persistence with acceptable safety
- favorable long-term survival curves
- competitive advantage in safety or response depth leading to broader formulary placement
Commercial strategy: what determines vorasidenib uptake and payer behavior?
Short answer: Payer coverage will center on clinical differentiation, eligibility criteria clarity, and real-world persistence.
Payer levers that decide formulary position
- Evidence threshold for coverage in earlier lines
- Prior authorization based on IDH mutation status and disease stage
- Step therapy requirements after surgery, radiation, or chemotherapy
- Duration limits versus “until progression” policies
Provider behavior
- Neuro-oncology and neuro-surgery workflows determine referral timing and test ordering
- Multidisciplinary tumor boards influence adoption pace
Key Takeaways
- Vorasidenib’s near-term market depends on durable PFS benefit translating into earlier standard-of-care use in IDH-mutant low-grade glioma and oligodendroglioma.
- Clinical trial expansions (earlier-stage settings, combinations, biomarker-defined subgroups) are the primary value drivers after initial label.
- Patent and exclusivity timelines will control generic entry risk; a quantified date-accurate exclusivity and litigation map requires the exact Orange Book listing tied to the approved NDA.
- Uptake is sensitive to molecular testing adoption, payer prior authorization rules, and real-world persistence for long-duration oral therapy.
FAQs
- What trial endpoints for vorasidenib most influence OS adoption by clinicians?
- How does IDH1 vs IDH2 mutation status affect vorasidenib uptake and expected benefit?
- What are the main drivers of payer prior authorization for vorasidenib in low-grade glioma?
- What combination strategies with vorasidenib are most likely to expand label indications?
- What settlement dynamics typically govern generic entry timing for high-profile oncology small molecules like vorasidenib?
References (APA)
- (No sources cited due to missing drug-specific Orange Book, NDA, patent, litigation, and trial result documents required for a factual update.)
